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Background: Experimental animal studies and one population-based study have suggested an increased risk for
adverse neurodevelopmental outcome after prenatal exposure to SSRIs. We describe the methods and design of a
population-based study examining the association between prenatal SSRI exposure and neurodevelopment until
age 14.
Methods and design: This is a cohort study of national registers in Finland: the Medical Birth Register, the Register
of Congenital Malformations, the Hospital Discharge Register including inpatient and outpatient data, the Drug
Reimbursement Register, and the Population Register. The total study population includes 845,345 women and
their live-born, singleton offspring aged 14 or younger and born during Jan 1st 1996-Dec 31st 2010. We will
compare the prevalence of psychiatric and neurodevelopmental outcomes in offspring exposed prenatally to SSRIs
to offspring exposed to prenatal depression and unexposed to SSRIs. Associations between exposure and outcome
are assessed by statistical methods including specific modeling to account for correlated outcomes within families
and differences in duration of follow-up between the exposure groups. Descriptive results. Of all pregnant women
with pregnancy ending in delivery (n = 859,359), 1.9% used SSRIs. The prevalence of diagnosed depression and
depression-related psychiatric disorders within one year before or during pregnancy was 1.7%. The cumulative
incidence of registered psychiatric or neurodevelopmental disorders was 6.9% in 2010 among all offspring born
during the study period (age range 0–14 years).
Discussion: The study has the potential for significant public health importance in providing information on
prenatal exposure to SSRIs and long-term neurodevelopment.
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Safety of the selective serotonin reuptake inhibitors
(SSRIs) during pregnancy is a question of major clinical
importance as up to 6% of pregnant women are reported
to use SSRIs [1]. Every sixth pregnant woman suffers
from major depressive disorder, and while untreated pre-
natal depression can have devastating consequences for
the mother and her family, it has also been linked to
poor perinatal outcome [2,3]. SSRIs are not major tera-
togens but neonatal adaptation problems are common
after prenatal exposure [4-7] and an increased risk has
been observed for other perinatal complications includ-
ing persistent pulmonary hypertension [8-10]. Conse-
quently, both patients and clinicians frequently need to
balance between the risks of untreated depression and
the potential risks associated with continuing anti-
depressant treatment during pregnancy.
Serotonin has a crucial role in neural development
and maturation [11] and studies in rodents have demon-
strated that manipulation of serotonin (5-HT) levels by
exposing the animals to SSRIs at a vulnerable stage of
central nervous system development can lead to per-
manent behavioral changes, paradoxically presented as
increased depression and anxiety-related behavioral phe-
notypes [12-15].
In humans, long-term effects of prenatal SSRI expos-
ure on childhood neurodevelopment have not been ex-
tensively studied. While small, non-population based
cohort studies observed no excess risk by age four or
seven [16-18], one population-based study suggested an
increased risk of autism spectrum disorders in prenatally
exposed offspring [19]. A major challenge remains to
disentangle the effects of maternal depression and
maternal use of SSRIs on later neurodevelopment in
offspring. This study represents the epidemiological
part of an international, collaborative research pro-
ject which is part of a Conte Center project for the
Neuroscience of Mental Disorders at Columbia Uni-
versity (http://columbiapsychiatry.org). This innovative
collaboration consists of several linked research pro-
jects addressing the fundamental questions of altered
serotonin signalling and prenatal SSRI exposure on
brain structure, function, and long-term behavioural
outcomes. Other projects in this collaboration include
basic and experimental research with animal models,
and clinical neurobiological studies on infant/childhood
outcomes following prenatal SSRI exposure. These
studies will help to interpret and validate our findings
derived from epidemiologic research, while our find-
ings may help generate novel hypotheses to be tested
in animal models. This concept of translating basic re-
search findings to epidemiology and vice versa constitu-
tes a model of bidirectional translational epidemiology
[20]. Because of the steadily increasing use of SSRIsduring pregnancy, this is one of the most challenging
questions in prenatal psychiatric epidemiology at present
and carries significant public health importance.
The objective of the nationwide Finnish Register-
Based Study on Infant and Childhood Neurodevelop-
mental Outcomes Following Prenatal Exposure to
Selective Serotonin Reuptake Inhibitors (FinESSI) is to
investigate if prenatal SSRI exposure increases the risk
of adverse psychiatric or neurodevelopmental outcome
until age 14, controlling for maternal depression. The
aim of this methods paper is to describe the study de-
sign, the national registers included in the study, and
linkage of the registers. We also report the trends in
SSRI use during pregnancy during the study period, the
prevalence of diagnosed depression and depression-
related psychiatric disorders in the pregnant population,
and the cumulative incidence of psychiatric and neurode-
velopmental disorders in the whole offspring population.
Methods and design
Overview of the study design
This is a population-based, prospective cohort investiga-
tion. All data are collected from national, population-
based registers. Psychiatric and neurodevelopmental
diagnoses in offspring exposed prenatally to SSRIs are
compared to unexposed offspring controlling for mater-
nal depression (Figure 1). The sampling frame includes
845,345 offspring consisting of all singleton live births in
Finland (approximately 56,500 births per year) between
Jan 1st 1996 and Dec 31st 2010, identified from the Med-
ical Birth Register. Hence, the age range of children born
in this cohort will be from birth to age 14. Data on SSRI
purchases are collected from the Drug Reimbursement
Register. The follow-up for psychiatric and neurodeve-
lopmental disorders is based on collection of these diag-
noses from the Hospital Discharge Register. Data on
major congenital anomalies are collected from the Regis-
ter of Congenital Malformations, and parental back-
ground data from the Population Register. Detailed
description of the methods follows.
Description of the registers
The national Drug Reimbursement Register (DRR), main-
tained by the Social Insurance Institution in Finland
(KELA) since 1995, tracks drugs that have been pur-
chased from pharmacies and contains data on 99%
of reimbursed prescription drug purchases [21].
Prescription-only medicines deemed necessary for the
treatment of an illness are reimbursed under the Social
Insurance System which covers all permanent residents
in Finland. Drug purchases are reimbursed concomi-
tantly upon purchase at pharmacies and drugs are sup-
plied to the patient for a maximum of three months
at a time. Data in the register include the date of the
SSRI use
SSRI-exposed
Unexposed 1
Unexposed 2
Unexposed 3
No antidepressant or 
antipsychotic use 
Key 
Have
to
occur
Must 
not
occur
No antidepressant or antipsychotic use
No depression-related disorder
Antidepressant or 
antipsychotic use
No antidepressant or 
antipsychotic use
Depression-related disorder
Figure 1 Time-window criteria for definition of exposed and unexposed offspring. SSRI, selective serotonin reuptake inhibitor; Y, year; M,
months. SSRI exposed: Offspring exposed prenatally to SSRIs. Unexposed 1: All offspring unexposed prenatally to antidepressants and
antipsychotics, but mother treated for depression or depression-related disorder during pregnancy or within one year before pregnancy.
Unexposed 2: Offspring unexposed prenatally to antidepressants and antipsychotics but mother has used antidepressants or antipsychotics within
one year before pregnancy. Unexposed 3: Offspring unexposed prenatally to antidepressants and antipsychotics and mother has no history of
psychiatric treatment (inpatient or outpatient diagnosis or use of antidepressants or antipsychotics).
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Chemical (ATC) classification code indicating the gen-
eric name of the drug and the dose prescribed. KELA
also maintains the Special Reimbursement Register
since 1964 with data on several chronic illnesses re-
quiring continuous drug treatment, with available in-
formation on possible special reimbursement status
including indication for treatment. Over-the-counter
drugs or medications given to institutionalized persons
are not included in the register.
The national Medical Birth Register (MBR) was estab-
lished in 1987 and is maintained by the National Insti-
tute for Health and Welfare (THL). This computerized
registry collects data on maternal demographic charac-
teristics, medical history including reproductive history,
health-related behaviours, diagnoses during pregnancy
and delivery, and neonatal outcome data up to seven
days’ age. Data in the MBR are collected in a standard
form from all maternity hospitals and include all births,
including the occasional homebirths. All infants are
examined in the hospital by a paediatrician. All live
births and stillbirths with gestational age of 22 weeks or
more or birth weight of 500 grams or more are included
in the register. The register data are confirmed and com-
plemented from the maternity hospital records in cases
of conflicting or missing information. The definitions
and variables included in this registry are based on
established international concepts and use the 10th ver-
sion of the WHO International Classification of Diseases(ICD). Extensive review of the data, including cross-
checking with the data from the Finnish Population
Register and Cause-of-Death Register at Statistics
Finland indicate that the data are virtually complete
[22,23].
The national Hospital Discharge Register (HDR) con-
tains a hospital identification code and data on admis-
sion and discharge dates as well as primary and
secondary diagnoses (two for inpatient care and 20 for
outpatient care) at discharge. The register covers all hos-
pital inpatient episodes in public and private institutions
and outpatient hospital visits in public hospitals. The
diagnoses are coded using ICD-8 (1969–1986), ICD-9
(1987–1995), and ICD-10 since 1996. Data on hospital
discharges are available from 1969, and data on all con-
tacts in outpatient clinics are available from 1998 until
the present. These registries will be used to identify the
recorded diagnoses for all psychiatric hospital admis-
sions since 1969 for parents and grandparents, as well as
hospital admission care (since birth) and outpatient psy-
chiatric contacts (since birth, starting from 1998) for the
child. The HDR data have been validated for psychiatric
diagnoses and are considered good [24-26]. In Finland,
all children attend regularly child welfare clinics where
medical examinations are performed by a trained public
health nurse or a physician, and which are mandatory
and free of charge. Data from these clinics are entered
into the hospital and outpatient registries if the child is
referred for specialized care for identified conditions.
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chiatric and neurodevelopmental disorders. Annual
examinations are further performed for all school chil-
dren and when indicated, a referral is made to special
health care. All diagnoses made by these health care pro-
viders are recorded in the inpatient and outpatient
registries.
The national Register of Congenital Malformations
(RCM), maintained by THL, receives comprehensive
data on congenital anomalies including live births, still-
births and fetuses from pregnancy terminations due to
severe fetal anomaly, all with at least one detected major
congenital anomaly including major structural anomal-
ies, chromosomal defects and congenital hypothyroidism,
classified and coded according to the 9th version of the
ICD classification. Minor anomalies are excluded princi-
pally according to the exclusion list of the European Sur-
veillance of Congenital Anomalies, EUROCAT [27]. Data
are collected from hospitals, health-care professionals
and cytogenetic laboratories. The RCM also draws upon
data from the Medical Birth Register and other relevant
health registers. The diagnoses obtained from these data
sources are confirmed by systematic contacts with hospi-
tals that have given treatment to the infant. Although the
register mainly collects data from the first year of the
infant’s life, it also includes subsequently detected con-
genital anomalies. The validity of the RCM is considered
good and has been ascertained in several studies [28-30].
The national Population Register (PR), maintained by
the Finnish Population Register Centre is a computer-
ized register that contains basic information, including
country of birth, marital status, marriages and divorces,
and deaths of all Finnish citizens and other citizens res-
iding permanently in Finland.
Exposure groups
The beginning of pregnancy has been calculated from
the best clinical estimation of gestational age at birth
(primarily based on ultrasound) as registered in the
MBR. SSRI drug purchase(s) (including fluoxetine, cita-
lopram, paroxetine, sertraline, fluvoxamine and escita-
lopram) during the period from one month before
pregnancy until the end of pregnancy indicate exposure
and the date of drug purchase is an indicator for begin-
ning of exposure. Length of exposure is defined by using
an algorithm based on data on the Defined Daily Dose
(DDD) obtained from the DRR. A sub-analysis to evalu-
ate overall SSRI exposure and exposure to individual
SSRIs during different trimesters is based on dividing
the trimesters into first (days 0–84 after the beginning of
pregnancy), second (days 85–182), and third trimester
(days 183 after the beginning of pregnancy until birth).
The total number of exposed children included in this
cohort is appr. 15,000.The unexposed comparison groups are described
below and in Figure 1. The object of the first two com-
parison groups is to control for maternal depression.
The unexposed group 1 includes all offspring of
women with no purchases of antidepressants (ATC
codes N06A, N06CA) or antipsychotics (N05A) from
three months before pregnancy until the end of preg-
nancy, but with a diagnosis of depression or other psy-
chiatric disorder related to depression or SSRI use
during the period from one year before until the end of
the index pregnancy (Figure 1). The diagnostic inclusion
criteria are schizophrenia, schizotypal and delusional
disorders (ICD-10 F20-F29), mood disorders (F30-F39),
and neurotic, stress-related and somatoform disorders
(F40-F48). Within the total pregnant population, 14,506
(1.7%) of women met the inclusion diagnosis (National
Institute for Health and Welfare, unpublished statistics,
Finland 2012). We estimate that more than half of these
women have used antipsychotics or antidepressants
within three months before pregnancy until the end of
pregnancy, leaving 5,000 to 6,000 offspring to be
included in this reference group.
The unexposed group 2 includes offspring of women
with antidepressant or antipsychotic drug purchases dur-
ing the period from 1 year until 3 months prior to preg-
nancy but no antidepressant or antipsychotic drug
purchases during the period of 3 months prior to preg-
nancy until end of pregnancy, excluding offspring
included in the first comparison group (Figure 1). The
use of SSRIs has been steadily increasing and at present,
10% of women of child-bearing age use antidepressants
in Finland, a figure which is nearly three times more
common than during pregnancy (National Institute for
Health and Welfare, unpublished statistics, Finland
2012). Accordingly, a total of 40,000 women (4-5%) of
the study population are expected to have used anti-
depressant medication prior to pregnancy. By subtract-
ing the SSRI -exposed group (n = 15,000) and the
‘unexposed 1’ group (n = 5,000) from these 40,000
women, we expect to obtain a total of 20,000 offspring
in this group. However, the numbers expected to be
obtained in ‘unexposed 1’ and ‘unexposed 2’ groups are
based on an estimate and may differ from the final num-
bers. Due to the relatively small expected numbers in
these groups no matching will be performed.
The unexposed group 3 serves as a ‘healthy’ back-
ground group and consists of offspring of pregnant
women with no purchases of antidepressants or antipsy-
chotics at any time prior to pregnancy or during preg-
nancy. In this group, the mother has neither diagnosis of
depression or a psychiatric disorder related to depres-
sion, nor SSRI use at any time prior to pregnancy or
during pregnancy. Two (2) unexposed per one (1)
exposed are selected randomly from a cohort matched
Population
All singleton live births in Finland 1996-2010: n=845,345 (MBR)
Identification of mothers with and without psychiatric
history
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matching will allow similar follow-up periods between
exposed and unexposed offspring. The total number of
offspring in this group will be appr. 30,000.
Definition of outcomes
We will focus on infant/childhood/diagnosed psychi-
atric and neurodevelopmental outcomes defined by
ICD-10 codes under chapter on Mental and behavioral
disorders’ (F00-F99), obtained from the HDR and in-
cluding e.g. depression (F32-39), anxiety disorders
(F40-42), mental retardation (F70-79), learning disabil-
ities and abnormalities in motor development (F80-83),
autism spectrum disorders (F84), attention deficit
hyperactivity disorder (F90), and oppositional and con-
duct disorders (F91-92).
Covariates and possible confounders to be considered
for adjustment in the analyses are presented in Table 1.
These data are virtually complete apart from data on
5 minute Apgar score which are only available from the
beginning of year 2004, and data on smoking which are
missing in 3% of the study material.
Data linkages
All linkages are made by the unique personal identity
code (PIC) which was introduced in 1964–1968 and is
assigned to all Finnish citizens and permanent residents
in Finland. The PIC is obligatory in every register and
remains unchanged throughout a person’s lifetime. First,Table 1 Covariates and possible confounders to be
considered for adjustment in the analyses
Mother Age
Marital status
Parity
Smoking
SES
Depression or depression-related psychiatric
diagnosis after the index pregnancy
Exposure to other psychiatric drugs or
suspected or established teratogens
Pregnancy Pregnancy-related diagnoses and complications
Mode of delivery
Perinatal events Preterm birth (<37 weeks)
Low 1 and 5 -minute Apgar score (<7)
Fetal hypoxia (pH < 7.25)
Low birth weight (<2.500 g)
Small for gestational age
Major congenital anomaly
Family Parental death, divorce and country of birth
Paternal and grandparents’ psychiatric diagnoses
SES, socio-economic status.offspring from the total population, exposed and unex-
posed to SSRIs in utero are identified using linkages
between the MBR and the DRR (drug reimbursement
data) (Figure 2). Second, these data are linked to the
HDR, and maternal exposure to depression and
depression-related disorders is defined according to in-
formation on maternal psychiatric diagnosis in this
register. Third, based on the criteria described previ-
ously (Figure 1) and the linkage procedure described
in Figure 2, the exposed-unexposed database is formed.
Fourth, pregnancy and infant data from the MBR and
data on infant and childhood psychiatric and neurode-
velopmental disorders from the HDR, and data on
covariates are added to the database. Identification of
biological fathers and grandparents and information on
parental background data are obtained from the PR.
The database is further expanded to include informa-
tion on paternal and grandparents’ psychiatric diagno-
ses from the HDR, and information on perinatal and
infant health outcomes from the MBR and the RCM.
The utilization of sensitive health register data for sci-
entific research and the data linkages has been approvedDatabase of 
exposed and 
unexposed groups
- SSRI-exposed
- Unexposed 1
- Unexposed 2
- Unexposed 3
Maternal history of treated psychiatric disorders in inpatient
(1969-2010) and public outpatient units (1998-2010) (HDR)
Identification of mothers with and without antidepressant
and/or antipsychotic use
Prescribed medication before or during pregnancy (1996-2010) 
(DRR)
Subanalyses
Trimester, individual
SSRI, dose (DRR)
Outcomes in offspring
- Psychiatric and 
neurodevelopmental disorders
by age 14 (HDR)
- Perinatal events (MBR)
- Major malformations (RCM)
Covariates
Maternal demographic data, 
perinatal/obstetric events (MBR);
maternal depression after index
pregnancy, fathers’ and 
grandparents’ medical history of 
psychiatric disorders (HDR, PR);
marital status, divorces, parents’ 
country of birth, SES (PR)
Figure 2 Flow chart of the register-based sources of
information used in the study. MBR, Medical Birth Register; RCM,
Register of Congenital Malformations; DRR, Drug Reimbursement
Register; HDR, Hospital Discharge Register; SSRI, selective serotonin
reuptake inhibitor; PR, Population Register; SES, socio-economic
status.
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authority. The study protocol was approved by the Insti-
tutional Ethical Review Board at THL and by the Institu-
tional Review Board of the New York State Psychiatric
Institute. Since the study subjects were not contacted,
informed consent was not required.
Statistical analyses
All data are anonymized and coded prior to statistical
analysis. The incidence of specific offspring outcomes
are compared between exposed and unexposed off-
spring. Univariate analyses are used to study demo-
graphic differences between the study cohorts, and
logistic regression to assess the association between pre-
natal SSRI exposure and infant/childhood neurodevelop-
mental outcomes. Random-intercept logistic regression
models are used to account for correlated outcomes
within families (siblings), and Cox proportional hazards
regression analyses to study potential differences in dur-
ation of follow-up between exposed and unexposed
cohorts. In addition, we will utilize a class of multivariate
failure time frailty models [31] to assess the effect of
SSRI exposure on the specified outcomes, with subject-
specific gamma frailties accounting for the correlation in
the times to diagnosis of the different outcomes. Further
analyses will focus on differences in outcome variables
according to trimester of exposure and on individual
drug level considering drug dose.
Statistical power
With 15,000 exposed infants, the study has 80% power
to detect a 1.3-fold increase in prevalence of perinatalFigure 3 Time-trend in antidepressant use among pregnant women i
drug purchases from one month before until the end of pregnancy. SSRI, soutcomes and psychiatric disorders that have a preva-
lence of 1% in the entire cohort (alpha = 0.05, two-
sided); for disorders that have prevalences of 3% and 5%,
we have 80% power to detect 1.2-fold and 1.1-fold
increases in prevalence, respectively.
Descriptive results
The use of antidepressants within the whole pregnant
population and including all pregnancies ending in deliv-
ery (n = 859,359) increased steadily during the study
period from 0.6% in 1996 to 4.8% in 2010. This increase
was largely due to the increasing use of SSRIs, which
were used by 0.4% of pregnant women in 1996, and 3.8%
in 2010, while the use of tricyclic antidepressants
remained largely unchanged (Figure 3). The most com-
monly used SSRI was citalopram (0.8% of pregnant
women), followed by fluoxetine (0.4%) and sertraline
(0.3%). During pregnancy, SSRIs were most commonly
purchased during the first trimester or one month be-
fore pregnancy (1.6%), with a declining prevalence as
pregnancy advanced (0.8% of pregnant women in the
second trimester and 0.7% in the third trimester).
The prevalence of diagnosed depression and
depression-related psychiatric diagnoses (ICD-10 codes
F20-F48) in the whole pregnant population within the
period of one year before pregnancy until the end of
pregnancy was 1.7% (years 1996–2010). Only inpatient
data were available for years 1996–1997, accounting for
the lower prevalence in these years’ cohorts (Figure 4).
The cumulative incidence of any registered psychiatric
or neurodevelopmental disorder (ICD-10 F00-99) in the
study population including all live born singletonn Finland, years 1996–2010. The numbers include antidepressant
elective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
Figure 4 The annual prevalence of diagnosed depression and depression-related psychiatric disorders from one year before or during
pregnancy in women giving birth in Finland, years 1996–2010. Data on deliveries are linked to both outpatient (1998–2010) and inpatient
data (1996–2010) of the women.
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range 0–14 years), and 12.9% in 2010 among the oldest
offspring cohort (age 14, born in 1996).
Discussion
The FinESSI study represents a population-based birth
cohort study of SSRI use and infant/childhood outcomes
until age 14, capitalizing on a unique and highly valuable
sample consisting of all singleton offspring of women in
Finland who received SSRI’s during pregnancy from
1996–2010. The data in all the included national regis-
ters have high quality [24,32], and the population-based
setting allows for good generalization of the study
results.
These resources provide the study with several design
advantages, including minimization of ascertainment
bias and bias due to loss of follow-up. Further, the regis-
ters allow accurate assessment of SSRI dosage, timing
and duration of exposure. Based on the data obtained
from the Medical Birth Register, we are able to adjust
for several confounding influences and modifying factors
related to pregnancy and perinatal conditions which may
affect long-term neurodevelopment. By controlling for
paternal and grandparental history of psychiatric illness
and maternal psychiatric illness after the index preg-
nancy we can further adjust for potential genetic and en-
vironmental factors modifying outcome.
We observed a steadily increasing use of SSRIs in the
Finnish pregnant population, from 0.4% in 1996 to 3.8%
in 2010. This is in line with observations in other coun-
tries [1,33,34]. The prevalence of diagnosed maternaldepression and depression-related psychiatric disorders
was 1.7% in the whole pregnant population covering the
period of one year before pregnancy until delivery, and
increased during the study frame. Together with the in-
creasing use of SSRIs, this probably indicates a growing
awareness of the potential perinatal risks related to un-
treated prenatal depression [35].
Some limitations related to the methodology exist.
Register-based studies may be biased by lack of drug
compliance. Another limitation is that data on illicit
drug and alcohol use are not routinely collected in the
registers. Third, the study includes information on off-
spring who have been treated for psychiatric disorders,
but lacks information on untreated cases. However,
Finland has a health care system in which most services,
including universal coverage of psychiatric and medical
conditions, are provided and financed by the public sec-
tor (state and municipals). This increases the likelihood
of getting treatment when treatment is sought, thereby
increasing the likelihood of detecting these disorders in
the registries. Hence, both severe and mild cases are also
likely to be detected.
Conclusions
This study will provide information on the possible
long-term psychiatric and neurodevelopmental sequelae
of prenatal exposure to SSRIs. The national registers
offer an extremely valuable database for this purpose.
Given the widespread use of antidepressants, and the
considerable prevalence of depression and other psychi-
atric disorders during pregnancy, we expect that this
Malm et al. BMC Psychiatry 2012, 12:217 Page 8 of 9
http://www.biomedcentral.com/1471-244X/12/217research will have considerable implications for prescrib-
ing practices for clinicians. Through integration of this
project in a large research collaboration encompassing
many disciplines, this study serves as a model for transla-
tional epidemiology, maximising the strengths of experi-
mental, epidemiologic and clinical studies [20].
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